{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:17:19Z","timestamp":1777713439881,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012171","name":"Ontario Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["GA1-177700"],"award-info":[{"award-number":["GA1-177700"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cmi.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T06:58:54Z","timestamp":1755241134000},"page":"2048-2055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peginterferon \u03bb for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Christopher","family":"Kandel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia J.","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gillrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Powis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neill KJ.","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Atif","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Smookler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Booth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinthuka","family":"Jeganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaldo","family":"Stanislau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grishma","family":"Hirode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seham","family":"Noureldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Capraru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.08.003_bib1","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.08.003_bib2","article-title":"Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized platform clinical trial","volume":"6","author":"Reis","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.cmi.2025.08.003_bib3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with ivermectin among patients with COVID-19","volume":"386","author":"Reis","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2201662","article-title":"Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19","volume":"387","author":"Bramante","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.2023.1650","article-title":"Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial","volume":"329","author":"Naggie","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.08.003_bib8","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1001\/jama.2023.23363","article-title":"Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19: the ACTIV-6 randomized clinical trial","volume":"330","author":"Stewart","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.08.003_bib9","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","year":"2022","journal-title":"CMAJ"},{"key":"10.1016\/j.cmi.2025.08.003_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.08.003_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.08.003_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01204-23","article-title":"Harnessing the power of IFN for therapeutic approaches to COVID-19","volume":"98","author":"Viox","year":"2024","journal-title":"J Virol"},{"key":"10.1016\/j.cmi.2025.08.003_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910530","article-title":"IFN lambda deficiency contributes to severe COVID-19 outcomes","volume":"25","author":"Zaleska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2025.08.003_bib15","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s41467-021-22177-1","article-title":"Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial","volume":"12","author":"Jagannathan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.08.003_bib16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early Treatment with pegylated interferon lambda for Covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.08.003_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","article-title":"A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures","volume":"586","author":"Dinnon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2025.08.003_bib20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jhep.2014.07.022","article-title":"A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection","volume":"61","author":"Muir","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2025.08.003_bib21","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102250","article-title":"Safety and efficacy of inhaled interferon-\u03b21a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial","volume":"65","author":"Jagannathan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2025.08.003_bib23","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100044","article-title":"Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19","volume":"1","author":"Arribas","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cmi.2025.08.003_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.08.003_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2213-2600(22)00412-X","article-title":"Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care","volume":"11","author":"Shah","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2025.08.003_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103642","article-title":"Off balance: interferons in COVID-19 lung infections","volume":"73","author":"Akamatsu","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cmi.2025.08.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101303","article-title":"Type III IFNs: beyond antiviral protection","volume":"43","author":"Kotenko","year":"2019","journal-title":"Semin Immunol"},{"key":"10.1016\/j.cmi.2025.08.003_bib28","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial","volume":"77","author":"Etzion","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2025.08.003_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s13063-022-06689-9","article-title":"Overestimation of benefit when clinical trials stop early: a simulation study","volume":"23","author":"Liu","year":"2022","journal-title":"Trials"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25003945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25003945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:27:03Z","timestamp":1772882823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25003945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1198743X25003945"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.003","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peginterferon \u03bb for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}